Validation study compares Br-CReSP and SF-12 for health-related quality of life in nephrolithiasis, suggesting Br-CReSP is superior.
The validated Br-CReSP outperforms SF-12 in assessing HRQoL in Brazilian patients with kidney stones.
No takes yet. Share an insight, caveat, or question.
Danilovic et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: